Kenneth Steadman

1.6k total citations
28 papers, 1.1k citations indexed

About

Kenneth Steadman is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Kenneth Steadman has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Kenneth Steadman's work include Drug Transport and Resistance Mechanisms (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Kenneth Steadman is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Kenneth Steadman collaborates with scholars based in United States, Russia and India. Kenneth Steadman's co-authors include Susan E. Bates, Robert W. Robey, Orsolya Polgár, Kuniaki Morisaki, Prakash Mistry, Balázs Sarkadi, Csilla Özvegy‐Laczka, Yasumasa Honjo, Randolph E. Patterson and Edith Speir and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Kenneth Steadman

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenneth Steadman United States 16 611 543 174 160 123 28 1.1k
Katalin Német Hungary 17 839 1.4× 649 1.2× 177 1.0× 152 0.9× 54 0.4× 26 1.4k
Ken Ohmine Japan 21 528 0.9× 605 1.1× 147 0.8× 73 0.5× 41 0.3× 82 1.4k
Kieran L. O’Loughlin United States 20 928 1.5× 764 1.4× 230 1.3× 56 0.3× 40 0.3× 33 1.7k
Elizabeth Hopper-Borge United States 18 954 1.6× 638 1.2× 243 1.4× 103 0.6× 31 0.3× 20 1.5k
Ietje Kathmann Netherlands 23 550 0.9× 649 1.2× 180 1.0× 107 0.7× 23 0.2× 40 1.4k
D D Ross United States 13 1.1k 1.9× 698 1.3× 357 2.1× 47 0.3× 33 0.3× 15 1.4k
C.M. Kuiper Netherlands 15 1.1k 1.7× 665 1.2× 278 1.6× 147 0.9× 20 0.2× 21 1.4k
Akiko Tohgo Japan 18 526 0.9× 501 0.9× 87 0.5× 83 0.5× 29 0.2× 37 930
Jenai M. Kailey United States 13 303 0.5× 654 1.2× 127 0.7× 77 0.5× 24 0.2× 15 1.3k
K D Tutsch United States 17 544 0.9× 492 0.9× 36 0.2× 152 0.9× 122 1.0× 22 1.4k

Countries citing papers authored by Kenneth Steadman

Since Specialization
Citations

This map shows the geographic impact of Kenneth Steadman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Steadman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Steadman more than expected).

Fields of papers citing papers by Kenneth Steadman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Steadman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Steadman. The network helps show where Kenneth Steadman may publish in the future.

Co-authorship network of co-authors of Kenneth Steadman

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Steadman. A scholar is included among the top collaborators of Kenneth Steadman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Steadman. Kenneth Steadman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Parker, Gregory S., Julia I. Toth, Sarah Fish, et al.. (2024). Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11. Molecular Cancer Therapeutics. 23(10). 1446–1458. 3 indexed citations
2.
Steadman, Kenneth, Sungyong You, Yiwu Yan, et al.. (2023). Autonomous action and cooperativity between the ONECUT2 transcription factor and its 3′ untranslated region. Frontiers in Cell and Developmental Biology. 11. 1206259–1206259. 2 indexed citations
3.
Reis-Sobreiro, Mariana, Jie‐Fu Chen, Tatiana Novitskaya, et al.. (2018). Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. Cancer Research. 78(21). 6086–6097. 53 indexed citations
4.
Morley, Samantha, Sungyong You, Ji‐Young Choi, et al.. (2015). Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. Scientific Reports. 5(1). 12136–12136. 34 indexed citations
5.
Deeken, John F., Hongkun Wang, Deepa S. Subramaniam, et al.. (2015). A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer. 121(10). 1645–1653. 24 indexed citations
6.
Rudek, Michelle A., et al.. (2014). Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemotherapy and Pharmacology. 73(4). 729–736. 17 indexed citations
7.
Harris, Michael A., Krithika Bhuvaneshwar, Thanemozhi G. Natarajan, et al.. (2013). Pharmacogenomic characterization of gemcitabine response – a framework for data integration to enable personalized medicine. Pharmacogenetics and Genomics. 24(2). 81–93. 14 indexed citations
8.
Smaglo, Brandon G., Hongkun Wang, Kenneth Steadman, et al.. (2013). A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab.. Journal of Clinical Oncology. 31(15_suppl). TPS2624–TPS2624.
9.
Deeken, John F., Hongkun Wang, Jimmy J. Hwang, et al.. (2012). A phase I study of lapatinib (LPT) and cetuximab (CTX) in patients with CTX-sensitive solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 2590–2590. 1 indexed citations
10.
Li, Zhijie, et al.. (2010). Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. Cell Cycle. 9(9). 1830–1838. 33 indexed citations
11.
Dowdell, Kennichi, Lesley Pesnicak, Victoria Hoffmann, et al.. (2009). Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr−/− murine model of autoimmune lymphoproliferative syndrome (ALPS). Experimental Hematology. 37(4). 487–494. 43 indexed citations
12.
Deeken, John F., Robert W. Robey, Suneet Shukla, et al.. (2009). Identification of Compounds that Correlate with ABCG2 Transporter Function in the National Cancer Institute Anticancer Drug Screen. Molecular Pharmacology. 76(5). 946–956. 22 indexed citations
13.
Bates, Susan E., Zhirong Zhan, Kenneth Steadman, et al.. (2009). Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma. British Journal of Haematology. 148(2). 256–267. 64 indexed citations
14.
Piekarz, Richard, Erin R. Gardner, Zhirong Zhan, et al.. (2008). Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228. Cancer Research. 68. 5831–5831. 1 indexed citations
15.
Steadman, Kenneth, Wilfred D. Stein, Thomas Litman, et al.. (2008). PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors. Cell Cycle. 7(6). 818–829. 15 indexed citations
16.
Goldsmith, Merrill E., Kenneth Steadman, Alfredo Martı́nez, et al.. (2007). The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Molecular Cancer Therapeutics. 6(2). 496–505. 20 indexed citations
17.
Morisaki, Kuniaki, Robert W. Robey, Csilla Özvegy‐Laczka, et al.. (2005). Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemotherapy and Pharmacology. 56(2). 161–172. 177 indexed citations
18.
Robey, Robert W., Kenneth Steadman, Orsolya Polgár, et al.. (2004). Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition. Cancer Research. 64(4). 1242–1246. 296 indexed citations
19.
Speir, Edith, R. Greene, Kenneth Steadman, et al.. (1989). Contrasting effects of verapamil and nifedipine on pH of ischemic myocardium in the dog.. Journal of Pharmacology and Experimental Therapeutics. 248(2). 654–660. 3 indexed citations
20.
Finkel, Mitchell S., Eric S Marks, Randolph E. Patterson, et al.. (1986). Increased cardiac calcium channels in hamster cardiomyopathy. The American Journal of Cardiology. 57(13). 1205–1206. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katalin Német Breakdown of academic impact, for papers by Ken Ohmine Breakdown of academic impact, for papers by Kieran L. O’Loughlin Breakdown of academic impact, for papers by Elizabeth Hopper-Borge Breakdown of academic impact, for papers by Ietje Kathmann Breakdown of academic impact, for papers by D D Ross Breakdown of academic impact, for papers by C.M. Kuiper Breakdown of academic impact, for papers by Akiko Tohgo Breakdown of academic impact, for papers by Jenai M. Kailey Breakdown of academic impact, for papers by K D Tutsch
Rankless by CCL
2026